@article{ab442bc1521f4e4e9c360914ec1dd5ac,
title = "Sensitive Periods for Cerebellar-Mediated Autistic-like Behaviors",
abstract = "Despite a prevalence exceeding 1%, mechanisms underlying autism spectrum disorders (ASDs) are poorly understood, and targeted therapies and guiding parameters are urgently needed. We recently demonstrated that cerebellar dysfunction is sufficient to generate autistic-like behaviors in a mouse model of tuberous sclerosis complex (TSC). Here, using the mechanistic target of rapamycin (mTOR)-specific inhibitor rapamycin, we define distinct sensitive periods for treatment of autistic-like behaviors with sensitive periods extending into adulthood for social behaviors. We identify cellular and electrophysiological parameters that may contribute to behavioral rescue, with rescue of Purkinje cell survival and excitability corresponding to social behavioral rescue. In addition, using anatomic and diffusion-based MRI, we identify structural changes in cerebellar domains implicated in ASD that correlate with sensitive periods of specific autism-like behaviors. These findings thus not only define treatment parameters into adulthood, but also support a mechanistic basis for the targeted rescue of autism-related behaviors. A mechanistic understanding of and establishment of time windows for effective therapy (sensitive periods) for autism-related behaviors remain unknown. Tsai et al. delineate specific time windows for treatment of specific autism-relevant behaviors and evaluate underlying cellular, electrophysiological, and anatomic mechanisms for these sensitive periods.",
keywords = "Purkinje cell, autism, cerebellum, sensitive periods, treatment, tuberous sclerosis",
author = "Tsai, {Peter T.} and Stephanie Rudolph and Chong Guo and Jacob Ellegood and Gibson, {Jennifer M.} and Schaeffer, {Samantha M.} and Jazmin Mogavero and Lerch, {Jason P.} and Wade Regehr and Mustafa Sahin",
note = "Funding Information: M.S. received research funding from Roche, Novartis, Pfizer, and LAM Therapeutics unrelated to this project and served on the Scientific Advisory Boards of Sage Therapeutics, Takeda, Roche, and the PTEN Research Foundation and on the Professional Advisory Board of the Tuberous Sclerosis Alliance. Funding Information: P.T.T. acknowledges support from the Nancy Lurie Marks Foundation, the Hearst Foundation, and the National Institute of Neurologic Disorders and Stroke of the NIH (K08 NS083733). We also thank Dr. David Kwiatkowski for generous gift of Tsc1 floxed mice. M.S. acknowledges support from the Nancy Lurie Marks Family Foundation, the Boston Children's Hospital Boston Translational Research Program, and the Intellectual and Developmental Disabilities Research Center (U54 HD090255). J.P.L. acknowledges support from the Canadian Institutes of Health Research, the Ontario Brain Institute, and Brain Canada. Funding Information: P.T.T. acknowledges support from the Nancy Lurie Marks Foundation , the Hearst Foundation , and the National Institute of Neurologic Disorders and Stroke of the NIH ( K08 NS083733 ). We also thank Dr. David Kwiatkowski for generous gift of Tsc1 floxed mice. M.S. acknowledges support from the Nancy Lurie Marks Family Foundation , the Boston Children{\textquoteright}s Hospital Boston Translational Research Program, and the Intellectual and Developmental Disabilities Research Center ( U54 HD090255 ). J.P.L. acknowledges support from the Canadian Institutes of Health Research , the Ontario Brain Institute , and Brain Canada . Publisher Copyright: {\textcopyright} 2018 The Authors",
year = "2018",
month = oct,
day = "9",
doi = "10.1016/j.celrep.2018.09.039",
language = "English (US)",
volume = "25",
pages = "357--367.e4",
journal = "Cell Reports",
issn = "2211-1247",
publisher = "Cell Press",
number = "2",
}